6Y1 Stock Chart & Stats
€0.94
-€0.06(-3.43%)
At close: 4:00 PM EST
€0.94
-€0.06(-3.43%)
Day’s Range― - ―
52-Week Range€0.59 - €3.86
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€19.87M
Enterprise Value€193.19
Total Cash (Recent Filing)€19.06M
Total Debt (Recent Filing)€3.17M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding26,027,910
10 Day Avg. Volume6
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.07
Price to Sales (P/S)2.01
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€19.29M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal leverage lowers refinancing risk and preserves financial flexibility. This gives Integrum more capacity to fund clinical development, market expansion, or operational restructuring without substantial debt-servicing pressure.
Proven Historical Revenue Scale-UpStrong revenue expansion through 2024 indicates the company has previously converted its osseointegration offering into commercial growth. That history supports the possibility of renewed scaling if adoption, reimbursement, and execution challenges are addressed.
Recurring Implant-Related DemandThe implant system can create continuing demand beyond the initial procedure through replacement and additional components. This installed-base model may support repeat revenue and deeper provider relationships as the number of treated patients grows.
Bears Say
Recent Revenue ContractionThe recent reversal from prior growth weakens operating scale and makes fixed costs harder to absorb. Sustained contraction could limit investment capacity, reduce market penetration, and delay the path toward a more self-funded business model.
Severe Profitability DeteriorationNegative gross profit suggests that product economics, pricing, mix, or manufacturing costs are currently impaired, not merely that overhead is too high. Without correction, losses can erode equity and constrain sustainable commercial expansion.
Persistent Operating Cash BurnOngoing cash outflow from core operations means Integrum is not currently funding its activities internally. Reliance on cash reserves or external financing increases execution risk and could restrict investment in clinical adoption and geographic growth.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
Integrum AB Class B lowest stock price was €0.59 and its highest was €3.86 in the past 12 months.
What is Integrum AB Class B’s market cap?
Integrum AB Class B’s market cap is €19.87M.
When is Integrum AB Class B’s upcoming earnings report date?
Integrum AB Class B’s upcoming earnings report date is Sep 03, 2026 which is in 13 days.
How were Integrum AB Class B’s earnings last quarter?
Integrum AB Class B released its earnings results on Jun 04, 2026. The company reported -€0.059 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Integrum AB Class B overvalued?
According to Wall Street analysts Integrum AB Class B’s price is currently Overvalued.
Does Integrum AB Class B pay dividends?
Integrum AB Class B does not currently pay dividends.
What is Integrum AB Class B’s EPS estimate?
Integrum AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrum AB Class B have?
Integrum AB Class B has 26,027,910 shares outstanding.
What happened to Integrum AB Class B’s price movement after its last earnings report?
Integrum AB Class B reported an EPS of -€0.059 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.083%.
Which hedge fund is a major shareholder of Integrum AB Class B?
Currently, no hedge funds are holding shares in DE:6Y1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrum AB Class B
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-anchored prosthesis integrates directly with the patient's bone through osseointegration, thus circumventing the need for a conventional socket. A significant benefit of the OPRA system is its protective quality, helping to prevent bone fractures from accidental loads. Additionally, Integrum provides Neuromotus, a therapeutic technology designed to mitigate phantom limb pain following an amputation. These sophisticated implant systems are distributed worldwide to hospitals, clinics, and orthopedic professionals. The company was founded in 1962 and is based in Mölndal, Sweden.